Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
HU14.18K322A by Renaissance Pharma for Neuroblastoma: Likelihood of Approval
HU14.18K322A is under clinical development by Renaissance Pharma and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II...